UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment
Status:
Completed
Trial end date:
2018-05-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of Ixazomib on inducing osteoblast
activation as measured by bone markers and imaging in patients with relapsed/refractory
myeloma.